Healthcare
GeneDx Holdings Corp.(WGSWW)
Live Price
Offline$0.0078
+0.00% today
1Y Change
-94.23%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.99B
- Revenue Growth
- +40.0%
- EPS Growth
- +62.4%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GeneDx Holdings Corp. (WGSWW) is a Healthcare stock with a market cap of $1.99B and listed on NASDAQ. The stock last traded around $0.01 and down 94.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +40.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +62.4%, free cash flow +142.0% with operating margin -2.9% and ROIC -2.7%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WGSWW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+40.0% vs +7.6% peer median
Operating Margin
Below sector median
-2.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +40.0% and EPS at +62.4%, with operating margin around -2.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 23, 2026 | +36.9% | -26.9% | +2.2% | -41.8% |
2025 Oct 28, 2025 | -162.7% | +11.9% | +11.2% | -35.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WGSWW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WGSWW Max Drawdown
-97.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WGSWW and SPY.
Company Overview
GeneDx Holdings Corp.
NASDAQ Global Select
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
- Leadership
- Katherine A. Stueland
- Employees
- 1.0k
- Street Address
- North Tower
- Mailing
- Stamford, DE, 06902
- Region
- Stamford, DE, US
- Reporting Currency
- USD
- Investor Line
- 888 729 1206
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 307.4
- Price/Sales
- 4.7
- Price/Book
- 5.9
Growth
- Revenue
- +40.0%
- EPS
- +62.4%
- Free Cash Flow
- +142.0%
Profitability
- Gross Margin
- 68.5%
- Operating Margin
- -2.9%
- Net Margin
- -4.9%
- ROE
- -7.4%
- ROIC
- -2.7%
Balance Sheet
- Debt/Equity
- 0.49
- Current Ratio
- 2.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.